Rights to Ideal BioStent resorbable stent go to MultiCell Technologies
MultiCell Technologies Inc. (OTC:MCET) acquired the rights to the Ideal BioStent resorbable coronary stent for an undisclosed amount. The buyout, via Woonsocket, Rhode Island-based MultiCell’s Xenogenics Corp. subsidiary, also involves the exclusive, worldwide rights to patents covering the technology from Rutgers University. MultiCell touts the stent as the only one combining two drugs aimed at […]